Hydroxyurea Optimization through Precision Study (HOPS)

AGE: 6 months of age to 21 years old
GENDER: All

TYPE: Drug Study
HEALTHY PARTICIPANTS: No

CONDITION: Sickle Cell Anemia

Learn More About This Research Study

For more information, please call study coordinator, Amanda Rivera at 216-844-4908.

Study Purpose

University Hospitals is participating in this prospective, multi-center randomized trial to test whether the dosing of hydroxyurea using a novel precision medicine strategy for children with Sickle Cell Anemia (SCA) is superior to a standard step-wise dose escalation. The study will compare the standard dosing of hydroxyurea to a new individualized way of dosing to determine whether the new dosing strategy can result in better results. Hydroxyurea is normally dosed based only on your weight. This study will select a starting dose based on how each patient absorbs Hydroxyurea.

Who Can Participate

Patients 6 months of age to 21 years of age diagnosed with sickle cell anemia (HbSS, HbSD, HbS/B-thalassemia, or similarly severe SCA) may be eligible for to participate in this study.

If you are interested or want to learn more, please contact:

Study Coordinator:
Amanda Rivera
216-844-4908

Study ID
STUDYID20190803